Skip to main content

Table 1 Baseline demographic and clinical characteristics of subjects

From: Comparison of adherence between fixed and unfixed topical combination glaucoma therapies using Japanese healthcare/pharmacy claims database: a retrospective non-interventional cohort study

Variable Fixed combination (N = 309) Unfixed combination (N = 329)
n Percentage or mean ± SD n Percentage or mean ± SD
Sex, male 170 55.0 188 57.1
Age (years) 309 56.5 ± 10.2 329 57.1 ± 10.2
Body weight (kg) 210 61.8 ± 12.5 219 61.6 ± 11.0
Height (cm) 218 163.9 ± 9.2 226 164.4 ± 8.9
Body mass index (kg/m2) 210 22.9 ± 3.5 219 22.7 ± 3.1
Smoking
 Yes 33 10.7 32 9.7
 No 178 57.6 193 58.7
Medication for other indications
 Yes 63 20.4 74 22.5
 No 146 47.2 149 45.3
Fasting blood glucose (mg/dL) 200 97.0 ± 17.4 213 97.8 ± 15.4
HbA1c (NGSP) (%) 205 5.6 ± 0.6 216 5.6 ± 0.5
Urine glucose
 Negative (−) 208 67.3 221 67.2
 Positive (≥±) 4 1.3 2 0.6
Urine protein
 Negative (−) 192 62.1 207 62.9
 Positive (≥±) 24 7.8 19 5.8
Antihypertensive drug
 Yes 46 14.9 52 15.8
 No 163 52.8 171 52.0
Systolic blood pressure (mm Hg) 218 119.9 ± 15.5 226 120.3 ± 16.2
Diastolic blood pressure (mm Hg) 218 74.5 ± 11.3 226 75.6 ± 11.2
Total cholesterol (mg/dL) 64 207.3 ± 32.0 53 201.7 ± 35.9
Triglycerides (mg/dL) 217 107.9 ± 64.8 226 101.3 ± 66.6
HDL cholesterol (mg/dL) 217 64.6 ± 16.7 226 65.0 ± 16.9
LDL cholesterol (mg/dL) 217 124.4 ± 26.9 226 126.2 ± 31.2
Aspartate transaminase (U/L) 217 23.7 ± 9.3 226 23.0 ± 8.8
Alanine aminotransferase (U/L) 217 23.3 ± 14.6 226 23.5 ± 13.6
γ-GTP (U/L) 216 41.4 ± 49.1 226 37.6 ± 41.6
Common comorbidities
 Hypertension 92 29.8 110 33.4
 Cancer 90 29.1 114 34.7
 Hyperlipidemia 87 28.2 111 33.7
 Diabetes mellitus 85 27.5 97 29.5
 Insomnia 44 14.2 44 13.4
 Liver disorder 43 13.9 44 13.4
 Asthma or COPD 41 13.3 66 20.1
 Gastrointestinal ulcer 38 12.3 41 12.5
 Atherosclerosis or PAOD 31 10.0 38 11.6
 Anemia 30 9.7 33 10.0
 Coronary artery disease 26 8.4 33 10.0
 Heart failure 22 7.1 35 10.6
Locations
 8 regions
  Hokkaido 7 2.3 3 0.9
  Tohoku 14 4.5 6 1.8
  Kanto 176 57.0 207 62.9
  Chubu 38 12.3 37 11.2
  Kinki 38 12.3 36 10.9
  Chugoku 10 3.2 9 2.7
  Shikoku 2 0.6 2 0.6
  Kyushu 24 7.8 29 8.8
 Areas
  East Japan 210 68.0 220 66.9
  West Japan 99 32.0 109 33.1
 City size
  Tokyo and all GODMCs 255 82.5 289 87.8
  Other than GODMCs 54 17.5 40 12.2
  1. HBA1c hemoglobin A1c, NGSP National Glycohemoglobin Standardization Program, HDL high-density lipoprotein, LDL low-density lipoprotein, COPD chronic obstructive pulmonary disease, γ-GTP γ-glutamyl transpeptidase, PAOD peripheral arterial occlusive disease, GODMCs government ordinance-designed major cities
\